

# Medical Properties Trust, Inc. Reports First Quarter Results

May 1, 2025

#### Results Consistent with Expectations Following Mid-Quarter Debt Refinancing

BIRMINGHAM, Ala.--(BUSINESS WIRE)--May 1, 2025-- Medical Properties Trust, Inc. (the "Company" or "MPT") (NYSE: MPW) today announced financial and operating results for the first quarter ended March 31, 2025, as well as certain events occurring subsequent to quarter end.

- Net loss of (\$0.20) and Normalized Funds from Operations ("NFFO") of \$0.14 for the 2025 first quarter on a per share basis. First quarter net loss includes approximately \$73 million (\$0.12 per share) in impairments and fair market value adjustments related to Prospect Medical Group ("Prospect") and PHP Holdings ("PHP");
- Realized a 2.3% weighted average year-over-year inflation-based rent escalator for stabilized tenants;
- Commenced scheduled collection of cash rent from replacement operators at hospitals in Florida, Texas, and Louisiana;
- Completed a well-oversubscribed private offering of more than \$2.5 billion of senior secured notes due in 2032 at a blended coupon rate of 7.885% and simultaneously amended its approximately \$1.3 billion revolving line of credit, with a fully extended (at MPT's option) maturity, in June 2027, to share in the related collateral; and
- Paid a regular quarterly dividend of \$0.08 per share in April.

Edward K. Aldag, Jr., Chairman, President and Chief Executive Officer, said, "Our first quarter transactions and results are the culmination of two years of successful efforts to reduce debt, extend maturities, capture unrealized value and re-tenant hospital real estate at attractive and sustainable rents. MPT is well positioned to grow earnings from our existing in-place real estate portfolio, access capital for accretive growth in a uniquely attractive market and deliver growing dividends and other returns to our shareholders."

Included in the financial tables accompanying this press release is information about the Company's assets and liabilities, operating results, and reconciliations of net loss to NFFO, including per share amounts, all on a basis comparable to 2024 results.

#### PORTFOLIO UPDATE

Medical Properties Trust has total assets of approximately \$14.9 billion, including \$8.7 billion of general acute facilities, \$2.4 billion of behavioral health facilities and \$1.6 billion of post-acute facilities. As of March 31, 2025, MPT's portfolio included 393 properties and approximately 39,000 licensed beds leased to or mortgaged by 53 hospital operating companies across the United States as well as in the United Kingdom, Switzerland, Germany, Spain, Finland, Colombia, Italy and Portugal.

Across regions and asset types, operators are reporting solid top-line growth and stable EBITDARM coverage on both a year-over-year and sequential basis.

In Europe, hospitals continue to benefit from strong reimbursement and patient acuity trends. In the United Kingdom, three operators in MPT's portfolio have been nominated for Health Investors' Private Hospital Group of the Year – Circle Health, Priory, and Ramsay. In April, MPT agreed to fund its pro rata share of a modest new investment made by Infracore, its Swiss joint venture.

Performance in the United States continues to be driven by increased admissions in both general acute care facilities and behavioral care settings.

MPT remains encouraged by the performance of the new tenants to which it has transferred the operations of properties in Florida, Texas, Arizona, Louisiana and Pennsylvania. These operators remain focused on ramping capacity, driving higher volumes, and upgrading facilities. Through the first quarter, and with the exception of approximately \$100,000 in rent related to two Ohio facilities, MPT has collected all cash rent owed by these tenants.

Prospect's in-court restructuring process which commenced in January remains underway. In March, the Bankruptcy Court approved a settlement agreement between MPT, Prospect and certain other parties that will enable Prospect to sell its hospitals and the related real estate with MPT's cooperation. First quarter impairments and fair market value adjustments related to Prospect and PHP are based on third party appraisals and approved restructuring terms, and MPT's actual recoveries may ultimately differ from the adjusted book values.

#### **OPERATING RESULTS**

Net loss for the first quarter ended March 31, 2025 was (\$118 million) ((\$0.20) per share), compared to a net loss of (\$876 million) ((\$1.46) per share) in the year earlier period.

NFFO for the first quarter ended March 31, 2025 was \$81 million (\$0.14 per share), compared to \$142 million (\$0.24 per share) in the year earlier period. Compared to 2024's fourth quarter results, NFFO for 2025's first quarter reflects an increase in interest expense approximating \$14 million (\$0.025 per share) related to the previously described \$2.5 billion secured notes financing and a decrease in cash rent due to a catch-up of \$10 million (\$0.015 per share) cash rent received from an in-default tenant late in 2024's fourth quarter.

#### CONFERENCE CALL AND WEBCAST

The Company has scheduled a conference call and webcast for May 1, 2025 at 11:00 a.m. Eastern Time to present the Company's financial and operating results for the quarter ended March 31, 2025. The dial-in numbers for the conference call are 800-715-9871 (North America) and 646-307-1963 (International) along with passcode 5278552. The conference call will also be available via webcast in the Investor Relations section of the Company's website, www.medicalpropertiestrust.com.

A telephone and webcast replay of the call will be available beginning shortly after the call's completion. The telephone replay will be available through May 8, 2025, using dial-in numbers 800-770-2030 (North America) and 609-800-9909 (International) along with passcode 5278552. The webcast replay will be available for one year following the call's completion on the Investor Relations section of the Company's website.

The Company's supplemental information package for the current period will also be available on the Company's website in the Investor Relations section.

The Company uses, and intends to continue to use, the Investor Relations page of its website, which can be found at

www.medicalpropertiestrust.com, as a means of disclosing material nonpublic information and of complying with its disclosure obligations under Regulation FD, including, without limitation, through the posting of investor presentations that may include material nonpublic information. Accordingly, investors should monitor the Investor Relations page, in addition to following our press releases, SEC filings, public conference calls, presentations and webcasts. The information contained on, or that may be accessed through, our website is not incorporated by reference into, and is not a part of, this document.

#### About Medical Properties Trust, Inc.

Medical Properties Trust, Inc. is a self-advised real estate investment trust formed in 2003 to acquire and develop net-leased hospital facilities. From its inception in Birmingham, Alabama, the Company has grown to become one of the world's largest owners of hospital real estate with 393 facilities and approximately 39,000 licensed beds in nine countries and across three continents as of March 31, 2025. MPT's financing model facilitates acquisitions and recapitalizations and allows operators of hospitals to unlock the value of their real estate assets to fund facility improvements, technology upgrades and other investments in operations. For more information, please visit the Company's website at www.medicalpropertiestrust.com.

#### **Forward-Looking Statements**

(Amounts in thousands, except for per share data)

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements can generally be identified by the use of forward-looking words such as "may", "will", "would", "could", "expect", "intend", "plan", "estimate", "target", "anticipate", "believe", "objectives", "outlook", "guidance" or other similar words, and include statements regarding our strategies, objectives, asset sales and other liquidity transactions (including the use of proceeds thereof), expected re-tenanting of facilities and any related regulatory approvals, and expected outcomes from Prospect's Chapter 11 restructuring process. Forward-looking statements involve known and unknown risks and uncertainties that may cause our actual results or future events to differ materially from those expressed in or underlying such forward-looking statements, including, but not limited to: (i) the risk that the outcome and terms of the bankruptcy restructuring of Prospect will not be consistent with those anticipated by the Company; (ii) our success in implementing our business strategy and our ability to identify, underwrite, finance, consummate and integrate acquisitions and investments; (iii) the risk that previously announced or contemplated property sales, loan repayments, and other capital recycling transactions do not occur as anticipated or at all; (iv) the risk that MPT is not able to attain its leverage, liquidity and cost of capital objectives within a reasonable time period or at all; (v) MPT's ability to obtain or modify the terms of debt financing on attractive terms or at all, as a result of changes in interest rates and other factors, which may adversely impact its ability to pay down, refinance, restructure or extend its indebtedness as it becomes due, or pursue acquisition and development opportunities; (vi) the ability of our tenants, operators and borrowers to satisfy their obligations under their respective contractual arrangements with us; (vii) the ability of our tenants and operators to operate profitably and generate positive cash flow, remain solvent, comply with applicable laws, rules and regulations in the operation of our properties, to deliver high-quality services, to attract and retain qualified personnel and to attract patients; (viii) the risk that we are unable to monetize our investments in certain tenants at full value within a reasonable time period or at all; and (ix) the risks and uncertainties of litigation or other regulatory proceedings.

The risks described above are not exhaustive and additional factors could adversely affect our business and financial performance, including the risk factors discussed under the section captioned "Risk Factors" in our Annual Reports on Form 10-K and our Quarterly Reports on Form 10-Q, and as may be updated in our other filings with the SEC. Forward-looking statements are inherently uncertain and actual performance or outcomes may vary materially from any forward-looking statements and the assumptions on which those statements are based. Readers are cautioned to not place undue reliance on forward-looking statements as predictions of future events. We disclaim any responsibility to update such forward-looking statements, which speak only as of the date on which they were made.

#### MEDICAL PROPERTIES TRUST, INC. AND SUBSIDIARIES

### Consolidated Balance Sheets

March 31, 2025		December 31, 2024		
(Unaudited)		(A)		
\$	11,506,407	\$	11,259,842	
	1,004,228		1,057,770	
	22,754		34,019	
	121,442		119,912	
	12,654,831		12,471,543	
	(1,497,033)		(1,422,948)	
	11,157,798		11,048,595	
	673,482		332,335	
	26,695		36,327	
	755,585		700,783	
	1,189,238		1,156,397	
		(Unaudited) \$ 11,506,407 1,004,228 22,754 121,442 12,654,831 (1,497,033) 11,157,798 673,482 26,695 755,585	(Unaudited) \$ 11,506,407 \$ 1,004,228 22,754 121,442 12,654,831 (1,497,033) 11,157,798 673,482 26,695 755,585	

Investments in unconsolidated operating entities	418,074	439,578
Other loans	127,279	109,175
Other assets	 505,729	 471,404
Total Assets	\$ 14,853,880	\$ 14,294,594
Liabilities and Equity		
Liabilities		
Debt, net	\$ 9,465,400	\$ 8,848,112
Accounts payable and accrued expenses	451,269	454,209
Deferred revenue	25,481	29,445
Obligations to tenants and other lease liabilities	149,652	129,045
Total Liabilities	 10,091,802	 9,460,811
Equity		
Preferred stock, \$0.001 par value. Authorized 10,000 shares; no shares		
outstanding	-	-
Common stock, \$0.001 par value. Authorized 750,000 shares; issued and		
outstanding - 600,595 shares at March 31, 2025 and 600,403		
shares at December 31, 2024	600	600
Additional paid-in capital	8,590,422	8,584,917
Retained deficit	(3,825,178)	(3,658,516)
Accumulated other comprehensive loss	 (4,820)	 (94,272)
Total Medical Properties Trust, Inc. stockholders' equity	4,761,024	4,832,729
Non-controlling interests	1,054	1,054
Total Equity	 4,762,078	 4,833,783
Total Liabilities and Equity	\$ 14,853,880	\$ 14,294,594

(A) Financials have been derived from the prior year audited financial statements.

### MEDICAL PROPERTIES TRUST, INC. AND SUBSIDIARIES

## Consolidated Statements of Income

#### (Unaudited)

(Amounts in thousands, except for per share data)		For the Three Months Ended				
		March 31, 2025		March 31, 2024		
Revenues						
Rent billed	\$	165,190	\$	199,299		
Straight-line rent		40,127		44,736		
Income from financing leases		9,905		16,393		
Interest and other income		8,577		10,888		
Total revenues		223,799		271,316		
Expenses						
Interest		115,801		108,685		
Real estate depreciation and amortization		64,572		75,586		
Property-related (A)		7,035		4,818		
General and administrative		41,911		33,348		
Total expenses		229,319		222,437		
Other (expense) income						
Gain (loss) on sale of real estate		8,059		(1,423)		
Real estate and other impairment charges, net		(76,102)		(693,088)		
Earnings from equity interests		13,986		10,549		
Debt refinancing and unutilized financing costs		(3,796)		-		
Other (including fair value adjustments on securities)		(45,206)		(229,345)		
Total other expense		(103,059)		(913,307)		

Loss before income tax	(108,579)	(864,428)
Income tax expense	 (9,437)	 (10,949)
Net loss	(118,016)	(875,377)
Net income attributable to non-controlling interests	 (259)	 (248)
Net loss attributable to MPT common stockholders	\$ (118,275)	\$ (875,625)
Earnings per common share - basic and diluted:		
Net loss attributable to MPT common stockholders	\$ (0.20)	\$ (1.46)
Weighted average shares outstanding - basic	600,594	600,304
Weighted average shares outstanding - diluted	600,594	600,304
Dividends declared per common share	\$ 0.08	\$ -

(A) Includes \$1.9 million and \$2.3 million of ground lease and other expenses (such as property taxes and insurance) paid directly by us and reimbursed by our tenants for the three months ended March 31, 2025 and 2024, respectively.

### MEDICAL PROPERTIES TRUST, INC. AND SUBSIDIARIES

Reconciliation of Net Loss to Funds From Operations (Unaudited)

FFO information:       March 31, 2025       March 31, 2024         FFO information:       March 31, 2025       March 31, 2024         FFO information:       S       (118,275)       S       (875,625)         Participating securities' share in earnings       (117)       -       -         Net loss, less participating securities' share in earnings       (117)       -       -         Depreciation and amortization       76,891       94,243       -         (Gain) loss on sale of real estate       (8,059)       1,423       -       (779,959)         Other impairment charges, net       13,898       694,905       - <th>(Amounts in thousands, except for per share data)</th> <th></th> <th colspan="4">For the Three Months Ended</th>	(Amounts in thousands, except for per share data)		For the Three Months Ended			
Net loss attributable to MPT common stockholders       \$ (118,275)       \$ (875,625)         Participating securities' share in earnings       (117)       -         Net loss, less participating securities' share in earnings       \$ (118,392)       \$ (875,625)         Depreciation and amortization       76,891       94,243         (Gain) loss on sale of real estate       (8,059)       1,423         Real estate impairment charges       65,683       -         Funds from operations       \$ 16,123       \$ (779,959)         Other impairment charges, net       13,898       694,905         Litigation, barkruptcy and other costs       10,047       5,807         Share-based compensation (fair value adjustments) (A)       9,527       -         Non-cash fair value adjustments       26,609       221,276         Tax rate changes and other       1,102       (307)         Debt refinancing and unutilized financing costs       3,796       -         Norn-cash firet and interest revenue (B)       \$ 6,006       \$ 4,839         Non-cash rent and interest revenue (C)       \$ 55       57,48         Straight-line rent revenue from operating and finance leases       \$ (42,619)       \$ (146)         Depreciation and amortization       0,13       0,16       0,01       - <th></th> <th colspan="2">March 31, 2025</th> <th colspan="2">March 31, 2024</th>		March 31, 2025		March 31, 2024		
Participating securities' share in earnings       (117)       -         Net loss, less participating securities' share in earnings       \$ (118,392)       \$ (875,625)         Depreciation and amortization       76,891       94,243         (Gain) loss on sale of real estate       (8,059)       1,423         Real estate impairment charges       65,683       -         Funds from operations       \$ 16,123       \$ (779,959)         Other impairment charges, net       13,898       694,905         Litigation, bankruptcy and other costs       10,047       5,870         Share-based compensation (fair value adjustments) (A)       9,527       -         Non-cash fair value adjustments       26,609       221,276         Nor-cash fair value adjustments       26,609       21,102       \$ 141,785         Certain non-cash and related recovery information:       \$       8,138       7,633         Debt costs amortization       \$ 6,006       \$ 4,839       -         Non-cash rent and interest revenue (B)       \$ 5       \$ 5       -         <	FFO information:					
Participating securities' share in earnings       \$ (118.392)       \$ (875.625)         Depreciation and amortization       76.891       94.243         (Gain) loss on sale of real estate       (8.059)       1.423         Real estate impairment charges       65.683       -         Funds from operations       \$ 16,123       \$ (779,959)         Other impairment charges, net       13,898       694,905         Litigation, bankruptcy and other costs       10.047       5,870         Share-based compensation (fair value adjustments) (A)       9,527       -         Non-cash fair value adjustments       26,609       221,276         Normalized funds from operations       \$ 81,102       \$ 141,785         Certain non-cash and related recovery information:       \$       81,38       7,633         Share-based compensation (A)       \$ 8,138       \$ 7,633         Debt costs amortization       \$ 6,006       \$ 4,839         Non-cash rent and interest revenue (C)       \$ 526       \$ 5,748         Straight-line rent revenue (B)       \$ 42,619)       \$ (146,91)         Cash recoveries of non-cash rent and interest revenue (C)       \$ 526       \$ 5,748         Straight-line rent revenue from operating and finance leases       \$ (42,619)       \$ (1.46)         De	Net loss attributable to MPT common stockholders	\$	(118,275)	\$	(875,625)	
Depreciation and amortization       76,891       94,243         (Gain) loss on sale of real estate       (8,059)       1,423         Real estate impairment charges       65,683       -         Funds from operations       \$16,123       \$(779,959)         Other impairment charges, net       13,898       694,905         Litigation, barkruptcy and other costs       10,047       5,870         Share-based compensation (fair value adjustments) (A)       9,527       -         Non-cash fair value adjustments       26,609       221,276         Tax rate changes and other       1,102       (307)         Debt refinancing and unutilized financing costs       3,796       -         Norn-cash fair value adjustments       \$8,138       7,633         Debt costs amortization       \$8,138       \$7,633         Non-cash rent and interest revenue (B)       \$       -         Cash recoveries of non-cash rent and interest revenue (C)       \$5,256       \$5,748         Straight-line rent revenue from operating and finance leases       \$(42,619)       \$(47,246)         Per diluted share data:       0.013       0.16       0.011       -         Real estate impairment charges       0.11       -       -       -         Per diluted share data: <th>Participating securities' share in earnings</th> <th></th> <th>(117)</th> <th></th> <th>-</th>	Participating securities' share in earnings		(117)		-	
(Gain) loss on sale of real estate       (8,059)       1,423         Real estate impairment charges       65,683       -         Funds from operations       \$ 16,123       \$ (779,959)         Other impairment charges, net       13,898       694,905         Litigation, bankruptcy and other costs       10,047       5,870         Share-based compensation (fair value adjustments) (A)       9,527       -         Non-cash fair value adjustments       26,609       221,276         Tax rate changes and other       1,102       (307)         Debt refinancing and unutlized financing costs       3,796       -         Normalized funds from operations       \$ 81,102       \$ 141,785         Certain non-cash and related recovery information:       \$ 8,138       \$ 7,633         Share-based compensation (A)       \$ 8,138       \$ 7,633         Debt costs amortization       \$ 6,006       \$ 4,839         Non-cash rent and interest revenue (B)       \$ -< \$ -	Net loss, less participating securities' share in earnings	\$	(118,392)	\$	(875,625)	
Real estate impairment charges       65,683       -         Funds from operations       \$ 16,123       \$ (779,959)         Other impairment charges, net       13,898       694,905         Litigation, bankruptcy and other costs       10,047       5,870         Share-based compensation (fair value adjustments) (A)       9,527       -         Non-cash fair value adjustments       26,609       221,276         Tax rate changes and other       1,102       (307)         Debt refinancing and unutilized financing costs       3.796       -         Normalized funds from operations       \$ 81,102       \$ 141,785         Certain non-cash and related recovery information:       \$       8,138       \$ 7,633         Share-based compensation (A)       \$ 8,138       \$ 7,633         Debt costs amortization       \$ 6,006       \$ 4,839         Non-cash rent and interest revenue (B)       \$ -       \$ -         Cash recoveries of non-cash rent and interest revenue (C)       \$ 526       \$ 5,748         Straight-line rent revenue from operating and finance leases       \$ (42,619)       \$ (1.46)         Per diluted share data:       0.13       0.16       0.13       0.16         (Gain) loss on sale of real estate       0.11       -       0.11       -	Depreciation and amortization		76,891		94,243	
Funds from operations       \$ 16,123       \$ (779,959)         Other impairment charges, net       13,898       694,905         Litigation, bankruptcy and other costs       10,047       5,870         Share-based compensation (fair value adjustments) (A)       9,527       -         Non-cash fair value adjustments       26,609       221,276         Tax rate changes and other       1,102       (307)         Debt refinancing and unutilized financing costs       3,796       -         Normalized funds from operations       \$ 81,102       \$ 141,785         Certain non-cash and related recovery information:       \$ 6,006       \$ 4,839         Non-cash rent and interest revenue (B)       \$ -       \$ -         Cash recoveries of non-cash rent and interest revenue (C)       \$ 526       \$ 5,748         Straight-line rent revenue from operating and finance leases       \$ (42,619)       \$ (1.46)         Per diluted share data:       0.13       0.16         Net loss, less participating securities' share in earnings       0.13       0.16         Depreciation and amortization       0.13       0.16         (Gain) loss on sale of real estate       0.011       -         Real estate impairment charges       0.11       - <td>(Gain) loss on sale of real estate</td> <td></td> <td>( )</td> <td></td> <td>1,423</td>	(Gain) loss on sale of real estate		( )		1,423	
Other impairment charges, net       13,898       694,905         Litigation, bankruptcy and other costs       10,047       5,870         Share-based compensation (fair value adjustments) (A)       9,527       -         Non-cash fair value adjustments       26,609       221,276         Tax rate changes and other       1,102       (307)         Debt refinancing and unutilized financing costs       3,796       -         Normalized funds from operations       \$ 81,102       \$ 141,785         Certain non-cash and related recovery information:       \$       8,138       7,633         Debt costs amortization       \$ 6,006       \$ 4,839       -         Non-cash rent and interest revenue (B)       \$ -       \$ -       \$ -         Cash recoveries of non-cash rent and interest revenue (C)       \$ 526       \$ 5,748       \$ 5,748         Straight-line rent revenue from operating and finance leases       \$ (42,619)       \$ (146)       0.13       0.16         Ogin) loss on sale of real estate       0.011       -       -       -       0.11       -         Real estate impairment charges       0.111       -       0.111       -       0.111       -	Real estate impairment charges		65,683		-	
Litigation, bankruptcy and other costs10,0475,870Share-based compensation (fair value adjustments) (A)9,527-Non-cash fair value adjustments26,609221,276Tax rate changes and other1,102(307)Debt refinancing and unutilized financing costs3,796-Normalized funds from operations\$ 81,102\$ 141,785Certain non-cash and related recovery information:\$ 6,006\$ 4,839Share-based compensation (A)\$ 6,006\$ 4,839Non-cash rent and interest revenue (B)\$ -\$ -Cash recoveries of non-cash rent and interest revenue (C)\$ 526\$ 5,748Straight-line rent revenue from operating and finance leases\$ (42,619)\$ (47,246)Per diluted share data:Net loss, less participating securities' share in earnings\$ (0.20)\$ (1.46)Gianj loss on sale of real estate(0.01)-Real estate impairment charges0.11-Real estate impairment charges0.11-	Funds from operations	\$	16,123	\$	(779,959)	
Share-based compensation (fair value adjustments) (A)       9,527       -         Non-cash fair value adjustments       26,609       221,276         Tax rate changes and other       1,102       (307)         Debt refinancing and unutilized financing costs       3,796       -         Normalized funds from operations       \$       81,102       \$       141,785         Certain non-cash and related recovery information:       \$       8,138       \$       7,633         Share-based compensation (A)       \$       8,138       \$       7,633         Debt costs amortization       \$       6,006       \$       4,839         Non-cash rent and interest revenue (B)       \$       -       \$       -         Cash recoveries of non-cash rent and interest revenue (C)       \$       5266       \$       5,748         Straight-line rent revenue from operating and finance leases       \$       (42,619)       \$       (47,246)         Per diluted share data:       \$       0.13       0.16       0.13       0.16         (Gain) loss on sale of real estate       0.011       -       \$       0.11       -         Real estate impairment charges       0.11       -       1       -       1       -	Other impairment charges, net		13,898		694,905	
Non-cash fair value adjustments26,609221,276Tax rate changes and other1,102(307)Debt refinancing and unutilized financing costs3,796-Normalized funds from operations\$ 81,102\$ 141,785Certain non-cash and related recovery information:Share-based compensation (A)\$ 8,138\$ 7,633Debt costs amortization\$ 6,006\$ 4,839Non-cash rent and interest revenue (B)\$ - \$ -Cash recoveries of non-cash rent and interest revenue (C)\$ 526\$ 5,748Straight-line rent revenue from operating and finance leases\$ (42,619)\$ (47,246)Per diluted share data:Net loss, less participating securities' share in earnings\$ (0.20)\$ (1.46)Depreciation and amortization0.130.16(Gain) loss on sale of real estate0.11-Real estate impairment charges0.11-Cash recoveries0.11-	Litigation, bankruptcy and other costs		10,047		5,870	
Tax rate changes and other1,102(307)Debt refinancing and unutilized financing costs3,796-Normalized funds from operations\$81,102\$Certain non-cash and related recovery information:\$81,102\$Share-based compensation (A)\$\$8,138\$Debt costs amortization\$6,006\$4,839Non-cash rent and interest revenue (B)\$-\$Cash recoveries of non-cash rent and interest revenue (C)\$526\$5,748Straight-line rent revenue from operating and finance leases\$(42,619)\$(47,246)Per diluted share data:Net loss, less participating securities' share in earnings\$0.130.16(Gain) loss on sale of real estate0.11Real estate impairment charges0.110.11-0.110.11-0.11-0.11-0.11-	Share-based compensation (fair value adjustments) (A)		9,527		-	
Debt refinancing and unutilized financing costs3,796Normalized funds from operations\$Share-based compensation (A)\$Debt costs amortization\$Non-cash rent and interest revenue (B)\$Cash recoveries of non-cash rent and interest revenue (C)\$Straight-line rent revenue from operating and finance leases\$Per diluted share data:\$Net loss, less participating securities' share in earnings\$Depreciation and amortization\$(Gain) loss on sale of real estate0.11Real estate impairment charges0.11Cash represented to the state impairment charges1.11	Non-cash fair value adjustments		26,609		221,276	
Debt reinfailting and undificed inflation gostsNormalized funds from operations\$\$1,102\$\$	Tax rate changes and other				(307)	
Certain non-cash and related recovery information:         Share-based compensation (A)       \$ 8,138 \$ 7,633         Debt costs amortization       \$ 6,006 \$ 4,839         Non-cash rent and interest revenue (B)       \$ - \$ -         Cash recoveries of non-cash rent and interest revenue (C)       \$ 526 \$ 5748         Straight-line rent revenue from operating and finance leases       \$ (42,619) \$ (47,246)         Per diluted share data:       \$ (0.20) \$ (1.46)         Net loss, less participating securities' share in earnings       \$ (0.20) \$ (1.46)         Depreciation and amortization       \$ 0.13         (Gain) loss on sale of real estate       \$ 0.11         Real estate impairment charges       \$ 0.11	Debt refinancing and unutilized financing costs		3,796		-	
Share-based compensation (A)\$8,138\$7,633Debt costs amortization\$6,006\$4,839Non-cash rent and interest revenue (B)\$-\$-Cash recoveries of non-cash rent and interest revenue (C)\$526\$5,748Straight-line rent revenue from operating and finance leases\$(42,619)\$(47,246)Per diluted share data:Net loss, less participating securities' share in earnings\$(0.20)\$(1.46)Depreciation and amortization0.130.160.011-(Gain) loss on sale of real estate0.11Real estate impairment charges0.11	Normalized funds from operations	\$	81,102	\$	141,785	
Debt costs amortization\$6,006\$4,839Non-cash rent and interest revenue (B)\$-\$-Cash recoveries of non-cash rent and interest revenue (C)\$526\$5,748Straight-line rent revenue from operating and finance leases\$(42,619)\$(47,246)Per diluted share data:Net loss, less participating securities' share in earnings\$(0.20)\$(1.46)Depreciation and amortization0.130.160.130.16(Gain) loss on sale of real estate(0.01)Real estate impairment charges0.11Depreciation and amortization0.130.160.11(Data)0.11Depreciation and amortization0.11-(Data)0.12(Data)0.11-Depreciation and participating securities0.11Depreciation and amortization0.130.16(Data)0.16(0.01)Depreciation and amortization0.11Depreciation and amortization0.11Depreciation0.11Depreciation0.12Depreciation0.13Depreciation0.11Depreciation0.11Depreciation0.11Depreciation0.11Depreciation0.11Depreciation0.11Depreciation0.11Depreciation0.11Depreciation0.12	Certain non-cash and related recovery information:					
Non-cash rent and interest revenue (B)\$-\$-Cash recoveries of non-cash rent and interest revenue (C)\$526\$5,748Straight-line rent revenue from operating and finance leases\$(42,619)\$(47,246)Per diluted share data:Net loss, less participating securities' share in earnings\$(0.20)\$(1.46)Depreciation and amortization0.130.16(Gain) loss on sale of real estate(0.01)-Real estate impairment charges0.11-Depreciation and charges0.11-	Share-based compensation (A)	\$	8,138	\$	7,633	
Cash recoveries of non-cash rent and interest revenue (C)\$526\$5,748Straight-line rent revenue from operating and finance leases\$(42,619)\$(47,246)Per diluted share data:Net loss, less participating securities' share in earnings\$(0.20)\$(1.46)Depreciation and amortization0.130.16(Gain) loss on sale of real estate(0.01)-Real estate impairment charges0.11-0.11	Debt costs amortization		6,006	\$	4,839	
Straight-line rent revenue from operating and finance leases       \$ (42,619) \$ (47,246)         Per diluted share data:       * (0.20) \$ (1.46)         Net loss, less participating securities' share in earnings       0.13       0.16         Depreciation and amortization       0.13       0.16         (Gain) loss on sale of real estate       (0.01)       -         Real estate impairment charges       0.11       -	Non-cash rent and interest revenue (B)		-	\$	-	
Per diluted share data:       \$ (0.20)       \$ (1.46)         Net loss, less participating securities' share in earnings       0.13       0.16         Depreciation and amortization       0.13       0.16         (Gain) loss on sale of real estate       (0.01)       -         Real estate impairment charges       0.11       -	Cash recoveries of non-cash rent and interest revenue (C)		526	\$	5,748	
Net loss, less participating securities' share in earnings\$(0.20)\$(1.46)Depreciation and amortization0.130.160.130.16(Gain) loss on sale of real estate(0.01)Real estate impairment charges0.11	Straight-line rent revenue from operating and finance leases	\$	(42,619)	\$	(47,246)	
Depreciation and amortization0.130.16(Gain) loss on sale of real estate(0.01)-Real estate impairment charges0.11-	Per diluted share data:					
Depreciation and amortization0.130.16(Gain) loss on sale of real estate(0.01)-Real estate impairment charges0.11-	Net loss, less participating securities' share in earnings	\$	(0.20)	\$	(1.46)	
Real estate impairment charges 0.11 -			0.13		0.16	
	(Gain) loss on sale of real estate		(0.01)		-	
	Real estate impairment charges		0.11		-	
		\$	0.03	\$	(1.30)	

Other impairment charges, net	0.02	1.16
Litigation, bankruptcy and other costs	0.02	0.01
Share-based compensation (fair value adjustments) (A)	0.02	-
Non-cash fair value adjustments	0.04	0.37
Tax rate changes and other	-	-
Debt refinancing and unutilized financing costs	 0.01	 -
Normalized funds from operations	\$ 0.14	\$ 0.24
Certain non-cash and related recovery information:		
Share-based compensation (A)	\$ 0.01	\$ 0.01
Debt costs amortization	\$ 0.01	\$ 0.01
Non-cash rent and interest revenue (B)	\$ -	\$ -
Cash recoveries of non-cash rent and interest revenue (C)	\$ -	\$ 0.01
Straight-line rent revenue from operating and finance leases	\$ (0.07)	\$ (0.08)

Notes:

Investors and analysts following the real estate industry utilize funds from operations ("FFO") as a supplemental performance measure. FFO, reflecting the assumption that real estate asset values rise or fall with market conditions, principally adjusts for the effects of GAAP depreciation and amortization of real estate assets, which assumes that the value of real estate diminishes predictably over time. We compute FFO in accordance with the definition provided by the National Association of Real Estate Investment Trusts, or Nareit, which represents net income (loss) (computed in accordance with GAAP), excluding gains (losses) on sales of real estate and impairment charges on real estate assets, plus real estate depreciation and amortization, including amortization related to in-place lease intangibles, and after adjustments for unconsolidated partnerships and joint ventures.

In addition to presenting FFO in accordance with the Nareit definition, we disclose normalized FFO, which adjusts FFO for items that relate to unanticipated or non-core events or activities or accounting changes that, if not noted, would make comparison to prior period results and market expectations less meaningful to investors and analysts. We believe that the use of FFO, combined with the required GAAP presentations, improves the understanding of our operating results among investors and the use of normalized FFO makes comparisons of our operating results with prior periods and other companies more meaningful. While FFO and normalized FFO are relevant and widely used supplemental measures of operating and financial performance of REITs, they should not be viewed as a substitute measure of our operating performance since the measures do not reflect either depreciation and amortization costs or the level of capital expenditures and leasing costs (if any not paid by our tenants) to maintain the operating performance of our properties, which can be significant economic costs that could materially impact our results of operations. FFO and normalized FFO should not be considered an alternative to net income (loss) (computed in accordance with GAAP) as indicators of our results of operating operations or to cash flow from operating activities (computed in accordance with GAAP) as an indicator of our liquidity.

Certain line items above (such as depreciation and amortization) include our share of such income/expense from unconsolidated joint ventures. These amounts are included with all activity of our equity interests in the "Earnings from equity interests" line on the consolidated statements of income.

(A) Total share-based compensation expense is \$17.7 million for the quarter ended March 31, 2025 (including certain awards that are to be settled in cash). Cash-settled awards are typically recorded in accordance with GAAP at fair value and measured at each balance sheet date until settlement. The resulting fluctuations, which are primarily driven by changes in our stock price rather than operational performance, can introduce significant volatility in our earnings. To enhance comparability and provide a more stable view of performance over time, NFFO reflects a \$9.5 million adjustment this quarter to arrive at total share-based compensation expense using grant date fair value for all awards (including cash-settled awards) of \$8.1 million.

(B) Includes revenue accrued during the period but not received in cash, such as deferred rent, payment-in-kind ("PIK") interest or other accruals.

(C) Includes cash received to satisfy previously accrued non-cash revenue, such as the cash receipt of previously deferred rent or PIK interest.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250430431387/en/

Drew Babin, CFA, CMA Head of Financial Strategy and Investor Relations Medical Properties Trust, Inc. (646) 884-9809 dbabin@medicalpropertiestrust.com

Source: Medical Properties Trust, Inc.